Weekly Digest - Jan 2024

Weekly Digest - Jan 2024

16 Jan 2024: Johnson & Johnson acquires ambrx for $2 Billion to boost next-gen cancer therapies

  • Johnson & Johnson is acquiring Ambrx Biopharma for $2 billion in an all-cash merger
  • The acquisition aims to leverage Ambrx’s unique antibody-drug conjugate (ADC) technology, which effectively kills cancer cells while minimizing toxicities
  • The deal includes accelerating the Phase 1/2 APEX-01 study of ARX517 in advanced prostate cancer and progressing a pipeline of novel ADC product candidates
  • Ambrx’s innovative ADC technology incorporates synthetic amino acids, overcoming limitations of traditional conjugation technologies

For full story click here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home